L26/P-267 Day-3 versus Day-5 first vitrification in double-vitrified embryos undergoing single biopsy: impact on blastocyst viability
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Sheril und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does initial vitrification at the cleavage stage (Day-3) compared with the blastocyst stage (Day-5) influence blastocyst viability following double vitrification and a single trophectoderm biopsy? Summary answer Double vitrification at Day-3 or Day-5 showed comparable blastocyst development, while Day-3 vitrification yielded more embryos available for Day 5 biopsy, with similar clinical outcomes. What is known already In PGT cycles, trophectoderm biopsy followed by blastocyst vitrification is standard practice; however, logistical or other routine constraints may necessitate vitrification prior biopsy. Direct blastocyst vitrification prior biopsy is not always feasible in high-volume clinical settings. Cleavage-stage vitrification provides a reliable and biologically safe strategy to preserve embryos without imposing culture prolongation. While vitrification post-biopsy is well-established and associated with high survival and reassuring clinical outcomes, the cumulative effect of double vitrification and single biopsy remains unclear. Available evidence on double vitrification is limited, particularly data comparing different timings of first vitrification, at the cleavage versus blastocyst stage, remain scarce. Study design, size, duration Retrospective observational cohort study including 302 IVF cycles from 2017 to 2025, contributing 1,531 embryos (D3/BL group, 156 cycles, 897 embryos; D5/BL group, 146 cycles, 634 embryos) subjected to double vitrification and single biopsy at blastocyst stage for PGT. Participants/materials, setting, methods Embryos within a cycle were vitrified either at the cleavage stage or at the blastocyst stage. All embryos were warmed and biopsied only at the blastocyst stage and re-vitrified. Primary laboratory outcomes included utilization rate, blastulation timing, blastocyst quality and ploidy. Analyses were stratified by PGT indication (PGT-A-only vs PGT-M/A cycles). Mixed-effects logistic regression adjusted for maternal age accounted for clustering within cycles. Main results and the role of chance Survival after warming was ≥99% across all vitrification strategies. Among biopsied embryos, the initial vitrification stage (Day-3 vs Day-5) did not significantly affect ultimate Top/Good blastocyst quality in either stratum (PGT-A only: aOR 1.52, 0.85–2.74, P = 0.159; PGT-M/A: aOR 1.31, 0.78–2.20, P = 0.307). Increasing maternal age was independently associated with reduced odds of achieving Top/Good blastocyst quality in the PGT-M/A cohort (aOR 0.94 per year, 0.90–0.99, P = 0.011), but not in PGT-A-only cycles (P = 0.550). Utilization rate per MII (33.9% vs 30.2%), per 2PN (45.3% vs 41%) did not differ between strategies per cycle rates. However, among biopsied embryos, Day-5 biopsy occurred more frequently following Day-3 first vitrification group (29.1% vs 16.7%, P < 0.001). Euploidy rates were comparable between D3/BL and D5/BL strategies in both PGT-A-only (aOR 1.09, 0.67–1.78, P = 0.718) and PGT-M/A cycles (aOR 0.76, 0.35–1.64, P = 0.488). Maternal age was inversely associated with euploidy in PGT-A-only cycles (aOR 0.92 per year, 0.89–0.96, P < 0.001), with a borderline association in PGT-M/A cycles (P = 0.053). Post-transfer outcomes were comparable between strategies, with similar clinical pregnancy rates (66.7% vs 62.7%, NS) and ongoing/live birth rates (50.0% vs 52.2%, NS) for D3/BL versus D5/BL transfers. Limitations, reasons for caution Retrospective design and heterogeneity in PGT indications, and limited sample size. Wider implications of the findings Overall, these findings suggest that both approaches are clinically acceptable and support greater flexibility in laboratory workflows when embryo cryopreservation prior to biopsy is required. The higher proportion of blastocysts available for Day-5 biopsy in the Day-3 initial vitrification group maybe relevant when considering biopsy timing strategies. Trial registration number No
Zitieren
APA
Sheril, M., Gonzales, R., Didar, H., Bayram, A., Abdala, A., Gallego, R. D., Fatemi, H., Nogueira, D., & Elkhatib, I. (2026). L26/P-267 Day-3 versus Day-5 first vitrification in double-vitrified embryos undergoing single biopsy: impact on blastocyst viability. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.603
Vancouver
Sheril M, Gonzales R, Didar H, Bayram A, Abdala A, Gallego RD, et al. L26/P-267 Day-3 versus Day-5 first vitrification in double-vitrified embryos undergoing single biopsy: impact on blastocyst viability. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.603
BibTeX
@article{Sheril2026,
author = {Sheril, M. and Gonzales, R. and Didar, H. and Bayram, A. and Abdala, A. and Gallego, R. Del and Fatemi, H. and Nogueira, D. and Elkhatib, I.},
title = {L26/P-267 Day-3 versus Day-5 first vitrification in double-vitrified embryos undergoing single biopsy: impact on blastocyst viability},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.603}
}
EUVIMED